Detalhe da pesquisa
1.
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.
Breast Cancer Res Treat
; 189(3): 689-699, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34414532
2.
Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.
Breast Cancer Res Treat
; 191(1): 223-224, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34625861
3.
Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01).
J Clin Oncol
; 38(3): 203-213, 2020 01 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-31804894